- The FDA IND approval marks a pivotal step for the company’s lead compound, known as Lucid-MS.
- What sets Quantum BioPharma’s proprietary treatment apart from most existing MS therapies is its mechanism.
- Lucid-MS previously completed phase 1 clinical trials, showing a favorable safety profile and being well tolerated.
A green light from the U.S. Food and Drug Administration (“FDA”) can turn years of laboratory work into a real shot at treating patients, and that is exactly what just happened for one biopharmaceutical company. Quantum BioPharma (NASDAQ: QNTM), a company focused on neurodegenerative and metabolic disorders, announced that the FDA has approved its Investigational New Drug (“IND”) application for Lucid-MS, clearing the path to phase 2 clinical testing of its multiple sclerosis (“MS”) candidate.
The announcement marks a pivotal step for the company’s lead compound, known as Lucid-MS. With the IND now approved, Quantum BioPharma can begin recruiting patients and administering the drug in a controlled clinical setting, something that…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Corporate Communications
IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]